跳至主要内容
临床试验/JPRN-UMIN000001297
JPRN-UMIN000001297未知未知

An exploratory study for development of neurophysiological indicators for prediction and evaluation of effectiveness of serotonin reuptake inhibitor fluvoxamine in patients with major depressive disorder - An exploratory study for development of neurophysiological indicators for effectiveness of fluvoxamine in major depression

Department of Neuropsychiatry, The University of Tokyo Hospital0 个研究点目标入组 20 人开始时间: 2008年8月4日最近更新:
适应症

试验速览

阶段
未知
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)No major cognitive deficits 2)Subjects taking fluvoxamine therapy 3)Subjects who cannot discontinue therapies listed below from 7 days prior to the trial start to the end point. 1.Thioridazine Hydrochloride, pimozide 2. Tizanidine hydrochloride 3.MAO inhibitors, Selegiline hydrochloride ( 14 days before starting the trial) 4.Cisapride 5.Any drugs under development 6.Any anticonvulsants 7.Any antipsychotic drugs 8.Antidepressants excluding Fluvoxamine 9.Lithium Carbonate 10.Chinese medicine effective on psychotic symptoms 11.Electroconvulsive therapy 12.Other physical treatments 4) Subjects with current DSM-IV personality disorder or mental retardation 5)Pregnant or lactating women 6)Subjects with severe hepatic dysfunction (AST>100 or ALT>100) 7)Subjects with severe renal dysfunction (BUN>25 or Cre>2.0) 8) Subjects with current or past history of convulsion 9)Subjects with current or past history of serious suicidal ideation or attempt (HAM-D item No.11 score > 3) 10)Subjects with past history of manic state or bipolar disorder 11)Subjects with brain organic disease, including current or past history of cerebrovascular disease and other related disorders 12)Past history of electric convulsive therapy 13)Subjects with cardiac failure which requires clinical treatment 14)Subjects with hemophilic disease or hemophilic factor which requires clinical treatment 15)Subjects with thyroidal dysfunction which requires clinical treatment 16)Ungiven notification of the disease name 17)Patient whom examination doctor judged improper as a trial subject

研究者

发起方
Department of Neuropsychiatry, The University of Tokyo Hospital

相似试验